Citations Report

Citation Index - Clinical Investigation [920 Articles]

The articles published in Clinical Investigation have been cited 920 times by eminent researchers all around the world. Following is the list of articles that have cited the articles published in Clinical Investigation.

  • 刘春花, 宋勇. 克里唑替尼在非小细胞肺癌治疗中的研究进展. 中华肺部疾病杂志 (电子版). 2014;7(1):78-80.

    View at Publisher | View at Google Scholar
  • 戴辉, 宋向群, 潘星辰, 彭海燕, 韦江, 周韶璋. mTOR 信号通路在克唑替尼诱导的 EML4-ALK 融合基因阳性肺癌细胞株 H2228 凋亡中的作用. 中国病理生理杂志. 2014;30(6):1103-9.

    View at Publisher | View at Google Scholar
  • Shimazawa R, Ikeda M. (2016) Drug–diagnostic co-development: challenges and issues. Expert review of molecular diagnostics ;16:187-204.

    View at Publisher | View at Google Scholar
  • Leuchs AK, Zinserling J, Brandt A, Wirtz D, Benda N (2015) Choosing appropriate estimands in clinical trials. Therapeutic Innovation & Regulatory Science 49:584-92.

    View at Publisher | View at Google Scholar
  • Camidge DR. 2012) ALK Rearrangements as a Therapeutic Target in Advanced Non-Small Cell Lung Cancer. International Journal.

    View at Publisher | View at Google Scholar
  • ДЕМИДОВА И, ЦЕПЕНЩИКОВА Е, БАРИНОВ А, ГАГАРИН И, САВЕЛОВ Н, ГРИНЕВИЧ В, ТЮЛЯНДИН С. Определение перестроек гена ALK в селектированной популяции российских больных немелкоклеточным раком легкого. Злокачественные опухоли. 2013(3 (7)).

    View at Publisher | View at Google Scholar
  • Permutt T. A taxonomy of estimands for regulatory clinical trials with discontinuations. Statistics in medicine 35: 2865–2875.

    View at Publisher | View at Google Scholar
  • Permutt T (2015) Sensitivity analysis for missing data in regulatory submissions. Statistics in medicine 35: 2876–2879.

    View at Publisher | View at Google Scholar
  • Leuchs AK, Brandt A, Zinserling J, Benda N (2016) Disentangling estimands and the intention‐to‐treat principle. Pharmaceutical Statistics 16: 12-19.

    View at Publisher | View at Google Scholar
  • Kenward MG (2015) Controlled multiple imputation methods for sensitivity analyses in longitudinal clinical trials with dropout and protocol deviation. Clinical Investigation. 5: 311-20.

    View at Publisher | View at Google Scholar
  • Shih WJ (2016) Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem. Statistics in Medicine 35: 2880-6.

    View at Publisher | View at Google Scholar
  • Permutt T, Li F (2016) Trimmed means for symptom trials with dropouts. Pharmaceutical Statistics. 16: 20-28.

    View at Publisher | View at Google Scholar
  • Lehrer E, Mullol J, Agredo F, Alobid I (2014) Management of chronic rhinosinusitis in asthma patients: is there still a debate?. Current allergy and asthma reports 14:1-6.

    View at Publisher | View at Google Scholar
  • Hall KT, Loscalzo J, Kaptchuk TJ (2015) Genetics and the placebo effect: the placebome. Trends in molecular medicine 21: 285-94.

    View at Publisher | View at Google Scholar
  • Colloca L, Grillon C (2014) Understanding placebo and nocebo responses for pain management. Current pain and headache reports 18: 1-7.

    View at Publisher | View at Google Scholar
  • Wendt L, Albring A, Benson S, Engler H, Engler A, et al. (2014) Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses. PLoS One 9:e107665.

    View at Publisher | View at Google Scholar
  • Benedetti F, Frisaldi E (2014) Creating placebo responders and nonresponders in the laboratory: boons and banes. Pain 4:165-7.

    View at Publisher | View at Google Scholar
  • Medoff ZM, Colloca L (2015) Placebo analgesia: understanding the mechanisms. Pain management 5: 89-96.

    View at Publisher | View at Google Scholar
  • MacPherson H, Hammerschlag R, Coeytaux RR, Davis RT, Harris RE, et al. (2016) Unanticipated insights into biomedicine from the study of acupuncture. The Journal of Alternative and Complementary Medicine 22: 101-7.

    View at Publisher | View at Google Scholar
  • Le Prell CG, Lobarinas E (2016) Clinical and translational research: challenges to the field. InTranslational Research in Audiology, Neurotology, and the Hearing Sciences 58: 241-265.

    View at Publisher | View at Google Scholar
  • Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB.(2013) Cutaneous effects of BRAF inhibitor therapy: a case series. Annals of oncology ;24:530-537. View at Publisher | View at Google Scholar
  • Trinh VA, Davis JE, Anderson JE, Kim KB. (2014) Dabrafenib therapy for advanced melanoma. Annals of Pharmacotherapy ;48;519-529.

    View at Publisher | View at Google Scholar
  • McDonnell T (2014) Take Two Sugar Pills and Call Me in the Morning Genetic tests can predict when placebos may be the best medicine.

    View at Publisher | View at Google Scholar
  • Trinh VA, You Y, Hwu WJ.(2014) Treatment of BRAF-mutated advanced cutaneous melanoma. Chinese clinical oncology ;3.

    View at Publisher | View at Google Scholar
  • Bloch ED (2014) Take Two Sugar Pills and Call Me in the Morning Genetic tests can predict when placebos may be the best medicine.

    View at Publisher | View at Google Scholar
  • McAleer MF, Kim DW, Trinh VA, Hwu WJ. Management of melanoma brain metastases.

    View at Publisher | View at Google Scholar
  • Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology 30: 1259-67.

    View at Publisher | View at Google Scholar
  • Cepelewicz J (2014)Take Two Sugar Pills and Call Me in the Morning Genetic tests can predict when placebos may be the best medicine.

    View at Publisher | View at Google Scholar
  • Todorović V, Martinović D.(2015) Skin toxicity of targeted therapy: Vemurafenib, first experiences from Montenegro. Sanamed ;10:109-114.

    View at Publisher | View at Google Scholar
  • Campbell J, King NB (2016) “Unsettling circularity”: Clinical trial enrichment and the evidentiary politics of chronic pain. BioSocieties: 1-26.

    View at Publisher | View at Google Scholar
  • Nepali K, Ojha R, Lee HY, Liou JP (2016) Early investigational tubulin inhibitors as novel cancer therapeutics. Expert opinion on investigational drugs 25:917-36.

    View at Publisher | View at Google Scholar
  • Wei YM, Xue ZK, Wang P, Zhao L. (2013) Formulation and pharmacokinetic evaluation of once-daily sustained-released system of nifedipine with solid dispersion and coating techniques. Archives of pharmacal research ;36:864-873.

    View at Publisher | View at Google Scholar
  • K Khurana R, Mahajan M, Kapoor S, Jain S, Singh B (2016) The Sojourn from Parenteral to Oral Taxanes using Nanocarrier Systems: A Patent Review. Recent patents on drug delivery & formulation 10:44-58.

    View at Publisher | View at Google Scholar
  • Jones ES, Rayner BL. The importance of guidelines: comment.

    View at Publisher | View at Google Scholar
  • Jang Y, Chung HJ, Hong JW, Yun CW, Chung H (2017) Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase. Acta Pharmacologica Sinica 38:133-45.

    View at Publisher | View at Google Scholar
  • Rayner BL. Erika SW Jones, MB BCh, FCP, Cert Nephrol, PhD, [email protected] gmail. com. (2014) CARDIOVASCULAR JOURNAL OF AFRICA.

    View at Publisher | View at Google Scholar
  • Rayner BL. (2014) The importance of guidelines: comment. Cardiovascular Journal of Africa ;25:296-297.

    View at Publisher | View at Google Scholar
  • Baldelli S, Cattaneo D, Pignatelli P, Perrone V, Pastori D, et al. (2016) Validation of an LC–MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma. Bioanalysis 8:275-83.

    View at Publisher | View at Google Scholar
  • Meier P. renal artery stenosis (2011) Medical therapy for atherosclerotic renal artery stenosis Clin. Invest. 1075–1077.

    View at Publisher | View at Google Scholar
  • Burgess JT, Croft LV, Wallace NC, Stephenson SA, Adams MN, et al. (2014) DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer 3:159-73.

    View at Publisher | View at Google Scholar
  • Fox CB, Haensler J (2013) An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert review of vaccines 12:747-58.

    View at Publisher | View at Google Scholar
  • A Day T, G Kublin J (2013) Lessons learned from HIV vaccine clinical efficacy trials. Current HIV research 11: 441-9.

    View at Publisher | View at Google Scholar
  • Day T, Morgan C (2013) Probing scientific questions to advance HIV vaccine development.

    View at Publisher | View at Google Scholar
  • Mercuri E, Muntoni F(2013) Muscular dystrophies. The Lancet ;381:8458-60.

    View at Publisher | View at Google Scholar
  • Eleftheriadou V (2013) Future horizons in vitiligo research: focusing on the recommendations of the Cochrane systematic review ‘Interventions for vitiligo’2010. British Journal of Dermatology 169: 67-70.

    View at Publisher | View at Google Scholar
  • McGreevy JW, Hakim CH, McIntosh MA, Duan D.(2015) Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Disease models & mechanisms. ;8:195-213.

    View at Publisher | View at Google Scholar
  • Oka Y, Tsuboi A, Nakajima H, Fujiki F, Nishida S, et al. (2016) WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives. InImmunotherapy of Cancer: 159-185.

    View at Publisher | View at Google Scholar
  • Hennekens CH, Dalen JE (2014)Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs. Trends in cardiovascular medicine 24: 360-6.

    View at Publisher | View at Google Scholar
  • Hennekens CH, Bjorkman DJ (2014) Evolving concepts in the primary prevention of cardiovascular disease: aspirin then and now. Future cardiology 10: 583-6.

    View at Publisher | View at Google Scholar
  • Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S.,et.al.. (2013) 24 month longitudinal data in ambulant boys with duchenne muscular dystrophy. PloS one ;8:e52512.

    View at Publisher | View at Google Scholar

Relevant Topics